13 IMW

TH

2011
PARIS

13 th International
MYELOMA WORKSHOP
PRELIMINARY PROGRAMME

May 3-6, 2011

Paris, Carrousel du Louvre
Abstracts Submission: from June 2010 to January 2011 
Registration: Opening June 2010
Welcome to Paris
Dear Colleagues and Friends,
It is both a privilege and an honour to invite you to attend the XIIIth International Myeloma Workshop to be held in
Paris from May 3 to 6, 2011.
In continuation with the previous organizers of this important biannual event, we aim to provide a compelling
scientific programme highlighting emerging advances in our understanding of the biology and treatment of mye-
loma disease. We also aim to stimulate lively debate discussion within the myeloma community and to contribute
to efficient diffusion of medical information.
Striving to further improve the quality of the meeting through various initiatives is another exciting task for us. The
location of the Workshop, in the Carrousel du Louvre which is right in the city centre, will ensure that you all enjoy
both the meeting and the fascinating city of Paris.
We are very much looking forward to welcoming you to Paris in May 2011!

Jean-Paul Fermand Thierry Facon Philippe Moreau

CALL FOR ABSTRACTS

SUBMIT AN ABSTRACT BEFORE JANUARY 10, 2011!
Submit an abstract based on your scientific work in one of the following categories:
- Section A: Basic Biology
- Section B: Bone Disease (including Imaging)
- Section C: Clinical Studies (including Transplantation)
- Section D: Preclinical Studies and New Drugs
- Section E: Epidemiology, Prognostic Factors, Quality of Life, Disease Complications and Treatment Toxicities
- Section F: Other Plasma Cell Dyscrasias
Abstracts will have to be submitted directly on the Internet.
They will be mainly considered for poster presentation, only a few abstracts will be chosen for oral presentation.
Accepted abstracts will be published in the «Haematologica Journal» (supplement).

Agenda
Submission opening: June 2010
Submission deadline: January 10, 2011
Notification of acceptance: March 2011

For further information on abstracts submission, please visit the website:

www.myeloma-paris2011.com
 PRELIMINARY PROGRAMME
Tuesday May 3 Wednesday May 4
8:00
Newly diagnosed MM < 65 yrs:
facts & questions
Chair: D. Reece & V. Hungria
How I treat? V. Rajkumar
What are the current asked questions? What are the current asked questions? Supportive care
Cooperative groups
10:00
OPENING TALK Coffee break
Visit of exhibition & posters area
10:30
Molecular pathways / Celgene
genetics Symposium
Chair: H. Avet-Loiseau & M. Chesi The Continuum of Care for the
Multiple Myeloma Patient
Chair: K. Anderson &
J.-L. Harousseau
12:30
Lunch Lunch
Visit of exhibition & posters area Visit of exhibition & posters area
14:00
Plasma cell Biology High-risk entities of MM:
Chair: B. Klein & N. Munshi from biology to treatment
Chair: K. Stewart & M. Kuehl
16:00
Coffee break Coffee break
Visit of exhibition & posters area Visit of exhibition & posters area
16:30
Bone disease: from Debate I:
physiopathology to treatment Post high dose therapy, nothing,
Chair: R. Bataille & B. Durie consolidation or maintenance?
Chair: J. Bladé ;
M. Attal & J.-P. Fermand
17:30
New bone and biological
exploration techniques in
18:30 plasma cell disorders
Chair: P. Greipp & R. Hájek
Waldenstrom’s award
19:00 Introduced by R. Kyle
Myeloma cast nephropathy &
19:15 AL amyloidosis
Chair: G. Merlini & R. Comenzo
20:30
Welcome reception at the prIME Oncology
Musée du Louvre Symposium supported by
Novartis Oncology
Strategies in Evolution:
Bone Targeted Therapy for Myeloma
21:30
23:00
Thursday May 5 Friday May 6
Newly diagnosed MM > 65 yrs: Consensus report
facts & questions Chair: N. Munshi
Chair: R. Alexanian & A. Palumbo Diagnosis criteria & criteria for
How I treat? B. Barlogie treatment and retreatment
Cooperative groups
Coffee break Coffee break
Visit of exhibition & posters area Visit of exhibition & posters area
Millennium Takeda Plenary abstract
& Janssen-Cilag session II
Symposium Chair: P. Richardson & M. Attal
Proteasome inhibition in multiple
myeloma and its clinical implications
Lunch
Visit of exhibition & posters area
Closing ceremony
Introducing IMW 2013: K. Shimizu
New drugs and therapeutic
approaches
Chair: J. San Miguel &
M. Boccadoro
Coffee break
Visit of exhibition & posters area
Debate II:
Should we treat some patients
with stage I MM?
Chair: M. Gertz ;
V. Mateos & S. Lonial
Plenary abstract session I
Chair: M. Cavo & G. Gahrton
Invited speakers: H. Lokhorst &
D. Joshua
Monoclonal immunoglobulin
and the nerve, Waldens-
trom’s macroglobulinemia
Chair: S. Treon & M. Delforge
 PRELIMINARY PROGRAMME

Tuesday May 3, 2011

I 10:00 - 10:30 OPENING TALK

I 10:30 - 12:30 M
 olecular pathways / genetics
Chair: H. Avet-Loiseau - FRA & M. Chesi - USA
Main lecture: “Germinal center and post germinal center differentiation:
the cradle of MM” ..................................................................................................................................................................... R. Dalla-Favera - USA
The different subtypes of MM ...................................................................................................................................................... R. Fonseca - USA
The genetic progression of MM . ...................................................................................................................................... H. Avet-Loiseau - FRA
Main lecture: MicroRNAs in MM ..................................................................................................................................................... C. Croce - USA
Panel discussion

I 12:30 - 14:00 Lunch

Visit of exhibition & posters area

I 14:00 - 16:00 P lasma cell Biology

Chair: B. Klein - FRA & N. Munshi - USA
Introduction lecture: “The UPR system”. ............................................................................................................................. A.-H. Lee - USA
Cytokine patways: which one to target? ....................................................................................................................................... B. Klein - FRA
mTOR complex pathway in MM . ....................................................................................................................................... A. Lichtenstein - USA
Role of syndecan-1 ................................................................................................................................................................ R.-D. Sanderson - USA
Panel discussion

I 16:00 - 16:30 Coffee Break

Visit of exhibition & posters area

I 16:30 - 18:30 B one disease: from physiopathology to treatment

Chair: R. Bataille - FRA & B. Durie - USA
Introduction lecture: ........................................................................................................................................................... G.-D. Roodman - USA
............................................................................................................................................................................................................................ S. Yaccoby - USA
............................................................................................................................................................................................................................... N. Giuliani - ITA

............................................................................................................................................................................................................................. B.-P. Ayati - USA

............................................................................................................................................................................................................................ P. Tassone - GBR

............................................................................................................................................................................................................... K. Vanderkerken - BEL

Panel discussion

I 18:30 - 19:15 W
 aldenstrom’s award
Introduced by R. Kyle - USA

I 20:30 - 23:00 Welcome reception at the Musée du Louvre

 Wednesday May 4, 2011

I 8:00 - 10:00 N ewly diagnosed MM < 65 yrs: facts & questions

Chair: D. Reece - CAN & V. Hungria - BRA
How I treat? . ........................................................................................................................................................................................ V. Rajkumar - USA
What are the current asked questions? . .................................................................................................................. Cooperative groups
EMN......................................................................................................................................................................................... P. Sonneveld - NED
CTN-BMT........................................................................................................................................................................................ S. Giralt - USA
Pethema. ..................................................................................................................................................................................... L. Rosiñol - ESP
MRC ............................................................................................................................................................................................ G. Morgan - GBR
IFM-DFCI .................................................................................................................................................................................... P. Moreau - FRA
Arkansas ................................................................................................................................................................................. B. Barlogie - USA

I 10:00 - 10:30 Coffee Break

Visit of exhibition & posters area

I 10:30 - 12:30 C elgene Symposium

The Continuum of Care for the Multiple Myeloma Patient
Chair: K. Anderson - USA & J.-L. Harousseau - FRA
Welcome and introduction:
The changing dynamic of multiple myeloma treatment ............................................................................... J.-L. Harousseau - FRA
Mechanisms of action and disease: intercellular events
and immunomodulation ................................................................................................................................................................. S. Lentzsch - USA
Mechanisms of action and disease: immune synapse .............................................................................................. M.-D. Davis - GBR
Optimizing current therapeutic options for relapsed/refractory
multiple myeloma . .............................................................................................................................................................. M.-A. Dimopoulos - GRE
The evidence supporting continuous therapy in multiple myeloma .......................................................................... S. Giralt - USA
From bench to bedside: combination regimens in the present and future
management of multiple myeloma ................................................................................................................................. K.-C. Anderson - USA
Close ................................................................................................................................................................................................... K.-C. Anderson - USA

I 12:30 - 14:00 Lunch

Visit of exhibition & posters area
I 14:00 - 16:00 H igh-risk entities of MM: from biology to treatment
Chair: K. Stewart - USA & M. Kuehl - USA
t(4& 14) and genomic instability in high-risk MM ...................................................................................................... L. Bergsagel - USA
The biochemical role of the histone methyltransferase MMSET in MM . ................................................................... A. Licht - SUI
Whole Genome Sequencing in high-risk MM ..................................................................................................................... K. Stewart - USA
What is GEP-defined high-risk MM? ........................................................................................................................... J. Shaughnessy - USA
The implications of high-risk MM to therapy ......................................................................... G. Morgan - GBR & H. Einsele - GER
Panel discussion

I 16:00 - 16:30 Coffee Break

Visit of exhibition & posters area

I 16:30 - 17:30 D ebate I:

Post high dose therapy, nothing, consolidation or maintenance
Chair: J. Bladé - ESP ; M. Attal - FRA & J.-P. Fermand - FRA

I 17:30 - 19:00 New

 bone and biological exploration techniques
in plasma cell disorders
Chair: P. Greipp - USA & R. Hájek - CZE
Introduction lecture:
“Bone imaging in MM: old scaffolds and new avenues” ............................................................................. M.-A. Dimopoulos - GRE
Whole-body MRI in MM ......................................................................................................................................................... H. Goldschmidt - GER
Pamidronate: Can the Dose be Lowered? ............................................................................................................................. P. Gimsing - DNE
Zoledronic Acid in the Management of MM ......................................................................................................................... J.-A. Child - GBR
Osteonecrosis of the Jaw . ....................................................................................................................................................................... N. Raje - USA
Should we use bone markers? . ...................................................................................................................................................... E. Terpos - GRE
Panel discussion

I 19:00 - 20:30 M
 yeloma cast nephropathy & AL amyloidosis
Chair: G. Merlini - ITA & R. Comenzo - USA
Introduction lecture: “New therapeutic approaches in AL” ............................................................................. M.-B. Pepys - GBR
Management of AL amyloidosis in 2011 . .................................................................................................................................. G. Merlini - ITA
Myeloma cast nephropathy ...................................................... N. Leung - USA & F. Bridoux - FRA & C.-A. Hutchinson - GBR

I 20:30 - 21:30 P rIME Oncology Symposium supported by Novartis Oncology

Strategies in Evolution: Bone Targeted therapy for Myeloma
 Thursday May 5, 2011

I 8:00 - 10:00 N ewly diagnosed MM > 65 yrs: facts & questions

Chair: R. Alexanian - USA & A. Palumbo - ITA
How I treat? . .......................................................................................................................................................................................... B. Barlogie - USA
What are the current asked questions? . ................................................................................................................. Cooperative groups
GIMEMA .................................................................................................................................................................................... A. Palumbo - ITA
Pethema ................................................................................................................................................................................... M. Mateos - ESP
GMMSG . ...................................................................................................................................................................................... C. Straka - GER
Hovon/Nordic .......................................................................................................................................................................... A. Waage - NOR
IFM .................................................................................................................................................................................................... T. Facon - FRA
MRC ............................................................................................................................................................................................... F. Davies - GBR

I 10:00 - 10:30 Coffee Break

Visit of exhibition & posters area

I 10:30 - 12:30 M
 illennium Takeda & Janssen-Cilag Symposium
Biological rationale for proteasome inhibition in multiple myeloma
and its clinical implications
Chair & speakers to be announced
Biological basis of proteasome inhibition in MM
Impact of proteasome inhibition in the treatment of MM
Update on clinical studies on proteasome inhibition in MM
Clinical management of peripheral neuropathy in MM

I 12:30 - 14:00 Lunch

Visit of exhibition & posters area
I 14:00 - 16:00 N ew drugs and therapeutic approaches
Chair: M. Boccadoro - ITA & J. San Miguel - ESP
Introduction lecture ................................................................................................................................................................... K. Anderson - USA
Preclinical basis for 2nd generation proteasome inhibitors ..................................................................................... D. Chauhan - USA
Carfilzomib and other proteasome inhibitors: Clinical data ...................................................................... A.-J. Jakubowiak - USA
New Imids . ....................................................................................................................................................................................................... M. Lacy - USA
Hypomethylating agents in MM ....................................................................................................... J. San Miguel - ESP & E. Ocio - ESP
Monoclonal antibodies in the treatment of MM . ........................................................................................................ S. Jagannath - USA
Panel discussion

I 16:00 - 16:30 Coffee Break

Visit of exhibition & posters area

I 16:30 - 17:30 Debate

 II:
Should we treat some patients with stage I MM?
Chair: M. Gertz - USA ; V. Mateos - ESP & S. Lonial - USA

I 17:30 - 19:00 P lenary abstract session I

Chair: M. Cavo - ITA & G. Gahrton - SWE
Invited speakers: H. Lokhorst - NDE & D. Joshua - AUS

I 19:00 - 20:30 M
 onoclonal immunoglobulin and the nerve, Waldenstrom’s
macroglobulinemia
Chair: S. Treon - USA & M. Delforge - BEL
Neuropathy in monoclonal gammopathy .................................................................................................................... E. Nobile-Orazio - ITA
Poems syndrome ........................................................................................................................................................................... A. Dispenzieri - USA
Update in the treatment of WM .............................................................................................................. S.Treon - USA & V. Leblond - FRA
 Friday May 6, 2011

I 8:00 - 10:00 C onsensus report

Chair: N. Munshi - USA
Diagnosis criteria & criteria for treatment and retreatment
Supportive care including vaccination and infection prophylaxis (E. Anaissie - USA), management of anemia
(H. Ludwig - AUT), vein thrombosis (A. Palumbo - ITA,), and bone disease (G.-D. Roodman - USA)

I 10:00 - 10:30 Coffee Break

Visit of exhibition & posters area

I 10:30 - 12:30 Plenary abstract session II

Chair: P. Richardson - USA & M. Attal - FRA
Invited speaker: A. Spencer - AUS

I 12:30 - 15:00 Closing ceremony

Introducing IMW 2013 . ..................................................................................................................................................................... K. Shimizu - JPN
 ACCESS

ROISSY CHARLES DE GAULLE

INTERNATIONAL AIRPORT

LA DÉFENSE
A1
PORTE DE
LA CHAPELLE
A14

PORTE
MAILLOT
Palais Royal
GARE A3
DU NORD
Tuileries Musée du Louvre Louvre - Rivoli
GARE
SAINT LAZARE GARE PORTE
1 1 7 1
DE L’EST DE BAGNOLET

Carrousel
du Louvre
Carrousel
A13 GARE
du Louvre
DE LYON
PORTE
PORTE GARE DE BERCY
D’AUTEUIL D’AUSTERLITZ
A4
GARE
MONTPARNASSE

PORTE D’ORLÉANS PORTE D’ITALIE

A6

Musée
d’Orsay

ORLY INTERNATIONAL
AIRPORT

CARROUSEL DU LOUVRE FLOOR PLAN

LO U V R E E N T R A N C E

99 rue S h o p p i n g a rc a d e
de Rivoli TRAITEUR

S a l le G a b r i e l D e lo r m e
2 3 5 0 sqm
S h o p p i n g a rc a d e
Conference Room

Fo y e r
H a l l C h a r le s V entra nce 1 2 0 0 sqm
M e z z a n i n e*
6 0 0 p l a ce s
6 0 0 sqm S a l le
S o u f f lo t
8 0 p la ce s

9 2 5 sqm

C a r ro u s e l G a rd e n Exhibition / Hospitality suits

/ Catering
*Mezzanine: meeting rooms and posters
S a l le
L e N ô t re TRAITEUR

1 9 0 0 sqm
 INFORMATION
Venue: Carrousel du Louvre
99 rue de Rivoli
75001 Paris - FRANCE

Dates: May 3-6, 2011

Official Web site: www.myeloma-paris2011.com

Registration: Before March 31, 2011:

Reduced fees for early registration: 700 euros
Reduced fees for early registration for IMS Member: 550 euros

From April 1st, 2011:

Regular fees: 800 euros
Reduced fees for IMS Member: 650 euros

Official language: English

Social event - Welcome Reception: Musée du Louvre

May 3, 2011

Professional Congress Organizer - Europa Organisation

Project Manager: Michaël Sertain
msertain@europa-organisation.com
Partnership Sales Representative: Afaf Yahiaoui
ayahiaoui@europa-organisation.com
Registration Insc-myeloma@europa-organisation.com
Hotel reservation Carlson Wagonlit wagonlit@europa-organisation.com

Committees - Organizing Committee
Jean-Paul FERMAND - Thierry FACON - Philippe MOREAU

Under the auspices of the International Myeloma Society and its Board of Directors
Robert A. KYLE (President) Vania HUNGRIA
Kenneth C. ANDERSON (Vice-President) Nikhil MUNSHI
INFORMATION

Douglas E. JOSHUA (Secretary) Antonio PALUMBO

Morie Abraham GERTZ (Treasurer) Jesús F. SAN MIGUEL
Brian G.M. DURIE Kazuyuki SHIMIZU
Jean-Luc HAROUSSEAU Pieter SONNEVELD

French Scientific Advisory Committee

Martine AMIOT Jean-Luc HAROUSSEAU
Bertrand ARNULF Cyrille HULIN
Michel ATTAL Bernard KLEIN
Hervé AVET LOISEAU Catherine PELLAT-DECEUNYNCK
Régis BATAILLE Claire MATHIOT

International Scientific Advisory Committee

Raymond ALEXANIAN Henk M. LOKHORST
Bart BARLOGIE Heinz LUDWIG
Peter Leif BERGSAGEL Maria-Victoria MATEOS
Joan BLADÉ Giampaolo MERLINI
Mario BOCCADORO Gareth J. MORGAN
Michele CAVO S. Vincent RAJKUMAR
Faith DAVIES Donna E. REECE
Meletios A. DIMOPOULOS Paul G. RICHARDSON
Hermann EINSELE John D. SHAUGHNESSY
Rafael FONSECA Andrew SPENCER
Gösta GAHRTON Keith STEWART
Sergio GIRALT Steven TREON
Nicola GIULIANI Karin VANDERKERKEN
Sundar JAGANNATH Anders WAAGE

Platinium sponsors

Bronze sponsors

Others sponsors